Publications by authors named "Ryoma Yamashita"
Article Synopsis
- Adjuvant durvalumab has become standard care for stage III NSCLC following the PACIFIC trial, but the impact of biomarkers like the Prognostic Nutritional Index (PNI) on patient outcomes remains unclear.
- In a study involving 56 patients from Fujieda Municipal General Hospital, a PNI cutoff value of 37.9 was found to predict overall survival (OS), with those in the low-PNI group experiencing significantly shorter progression-free survival and OS compared to the high-PNI group.
- The study indicates that pretreatment assessment of immune and nutritional status through PNI could serve as an independent predictor of survival for patients with stage III NSCLC receiving durvalumab after chemoradiation.
Background: Recently, deaths due to mucormycosis in immunocompromised hosts have increased; however, the clinical and pathological features of mucormycosis are not fully understood, especially in view of the associated high mortality and rare incidence in immunocompetent patients.
Case Presentation: We have described a rare autopsy case of a 67-year-old Japanese man with chronic obstructive pulmonary disease who contracted mucormycosis. He had not been on any immunosuppressants, and his immune functions were intact.